Literature DB >> 2894312

The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group.

.   

Abstract

The objective of the Beta-Blocker Pooling Project (BBPP) was to collect and analyse data from the major long-term secondary prevention trials in order to determine whether there are subsets of post-infarction patients who benefit to a greater or lesser extent from beta-blocker therapy than the average patient population. One-year all-cause mortality data from nine trials involving 13,679 patients were obtained. Overall, mortality was 24% lower in the beta-blocker group compared to the placebo group. However, there was heterogeneity among the results of the trials, which tested seven different beta-blockers. Subgroups with high placebo group mortality (e.g. patients with a history of previous myocardial infarction (MI), angina pectoris, mechanical or electrical complications, and digitalis usage) seemed to benefit particularly from beta-blocker treatment. These findings were consistent in the nine trials. Patients in the lower risk subgroups also appeared to benefit from beta-blockers, but this benefit was smaller in absolute terms and inconsistent across the trials. There was no evidence that treatment outcome was related to gender, baseline level of heart rate or blood pressure, or time of initiation of treatment after hospital admission. In conclusion, the Pooling Project indicates that high risk MI patients, without contraindications to beta-blockers, are the prime candidates for long-term therapy, but the lower risk patients may also receive some benefit.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894312

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  31 in total

Review 1.  Emergency management of acute myocardial infarction.

Authors:  S Maxwell
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 3.  Beta-adrenergic blocking drugs as antifibrillatory agents.

Authors:  Michael J Reiter
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

4.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

5.  Does beta-blocker prophylaxis improve survival after major noncardiac surgery?

Authors:  Marius Terblanche; Neill K J Adhikari; Damon C Scales
Journal:  CMAJ       Date:  2005-10-11       Impact factor: 8.262

6.  Sick population--treated population: the need for a better definition. The VALIDATA Group.

Authors:  J P Collet; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 8.  Lowering blood pressure. How far, how fast?

Authors:  A Roca-Cusachs
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist.

Authors:  Val Reilly; Margaret Cavanagh
Journal:  Pharm World Sci       Date:  2003-12

10.  Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction.

Authors:  Michael A Steinman; Andrew R Zullo; Yoojin Lee; Lori A Daiello; W John Boscardin; David D Dore; Siqi Gan; Kathy Fung; Sei J Lee; Kiya D R Komaiko; Vincent Mor
Journal:  JAMA Intern Med       Date:  2017-02-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.